Exagen Inc. (XGN) — SEC Filings
Exagen Inc. (XGN) — 28 SEC filings. Latest: 8-K (May 11, 2026). Includes 10 8-K, 8 SC 13G/A, 6 10-Q.
Overview
Exagen Inc. (XGN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 4, 2025: EXAGEN INC. reported a significant increase in revenue for the three months ended September 30, 2025, reaching $17.244 million, up from $12.507 million in the prior year, representing a 37.9% increase. For the nine months ended September 30, 2025, revenue grew to $49.944 million from $41.986 million
Sentiment Summary
Across 28 filings, the sentiment breakdown is: 2 bearish, 25 neutral, 1 mixed. The dominant filing sentiment for Exagen Inc. is neutral.
Filing Type Overview
Exagen Inc. (XGN) has filed 10 8-K, 6 10-Q, 1 DEF 14A, 2 10-K, 8 SC 13G/A, 1 8-K/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (28)
Risk Profile
Risk Assessment: Of XGN's 19 recent filings, 2 were flagged as high-risk, 12 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $17.244M |
| Net Income | $-7.087M |
| EPS | $-0.31 |
| Debt-to-Equity | 2.46 |
| Cash Position | $35.652M |
| Operating Margin | -18.0% |
| Total Assets | $62.823M |
| Total Debt | $29.095M |
Key Executives
- Dr. Dennis Horvath
- Kamal Singh
Industry Context
Exagen operates in the molecular diagnostics sector, focusing on autoimmune and autoimmune-related diseases. The market is characterized by rapid technological advancements, increasing demand for personalized medicine, and evolving reimbursement landscapes. Key competitors include larger diagnostic companies and specialized labs, all vying for market share through innovation and strategic partnerships.
Top Tags
10-Q (4) · financials (4) · medical-laboratories (3) · amendment (3) · institutional-ownership (3) · Biotechnology (2) · Net Loss (2) · Debt Financing (2) · corporate-governance (2) · shareholder-vote (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue (Q3 2025) | $17.244M | Increased 37.9% from $12.507M in Q3 2024 |
| Net Loss (Q3 2025) | $7.087M | Widened from $5.028M in Q3 2024 |
| Accumulated Deficit | $309.6M | As of September 30, 2025, indicating historical losses |
| Cash and Cash Equivalents | $35.652M | Increased from $22.036M at December 31, 2024, due to financing activities |
| Warrant Liability | $6.634M | New liability as of September 30, 2025, impacting total liabilities |
| Revenue Growth (Q3 YoY) | 37.9% | Percentage increase in revenue for the three months ended September 30, 2025 |
| Interest Expense (Q3 2025) | $1.319M | Increased from $0.562M in Q3 2024, contributing to wider losses |
| Net Proceeds from Public Offering | $18.6M | Received in May 2025, bolstering cash reserves |
| Initial Term Loan | $25.0M | Funded by Perceptive Credit Holdings IV, LP in April 2025 |
| AVISE CTD Revenue Contribution (Q3 2025) | 87% | Percentage of total revenue from the AVISE CTD test |
| Net Loss (Q2 2025) | $12.9M | Increased from $10.5M in Q2 2024, indicating worsening financial performance. |
| Net Loss (YTD June 2025) | $25.9M | Widened from $20.9M in the prior year, showing continued unprofitability. |
| New Term Loan (Tranche A) | $20.0M | Provides immediate liquidity but adds to the company's debt burden. |
| Delayed Draw Term Loan Facility | $10.0M | Additional potential debt, further increasing financial leverage. |
| Date of earliest event | May 7, 2025 | Reporting date for the 8-K |
Forward-Looking Statements
- {"claim":"Other institutional investors may re-evaluate their positions in Exagen Inc. following Wasatch Advisors LP's reduced stake.","entity":"Exagen Inc.","targetDate":"Q2 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Exagen Inc. (XGN)?
Exagen Inc. has 28 recent SEC filings from Jan 2024 to May 2026, including 10 8-K, 8 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of XGN filings?
Across 28 filings, the sentiment breakdown is: 2 bearish, 25 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Exagen Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Exagen Inc. (XGN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Exagen Inc.?
Key financial highlights from Exagen Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for XGN?
The investment thesis for XGN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Exagen Inc.?
Key executives identified across Exagen Inc.'s filings include Dr. Dennis Horvath, Kamal Singh.
What are the main risk factors for Exagen Inc. stock?
Of XGN's 19 assessed filings, 2 were flagged high-risk, 12 medium-risk, and 5 low-risk.
What are recent predictions and forward guidance from Exagen Inc.?
Recent forward-looking statements from Exagen Inc. include guidance on {"claim":"Other institutional investors may re-evaluate their positions in Exagen Inc. following Wasatch Advisors LP's r.